NASDAQ
Disc Medicine, Inc. (IRON)
♥ 712 Thanks from members
Disc Medicine, Inc. (IRON) faces a critical inflection point in Q4 2026, balancing widened financial losses and legal scrutiny from a past FDA Complete Response Letter against a newly aligned Phase 3 APOLLO trial pathway for bitopertin and progressing pipeline programs like selcodebart and DISC-3405.